Recursion Pharmaceuticals (MEX:RXRX) Beta: N/A (As of Jul. 12, 2026)


MEX:RXRX Recursion Pharmaceuticals Inc MEX:RXRX
57 GF Score
Price MXN62.20
GF Value MXN73.63
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-12), Recursion Pharmaceuticals's Beta is Not available.

Recursion Pharmaceuticals  (MEX:RXRX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Recursion Pharmaceuticals Beta Related Terms

Recursion Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Beta Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:RXRX
57GF Score
Recursion Pharmaceuticals Inc MEX:RXRX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of MXN62.20 is trading 15.5% below its estimated GF Value™ of MXN73.63. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:RXRX:

  • Beta: N/A
  • GF Value™: MXN73.63 vs. price of MXN62.20 (15.5% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:USA
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
57GF Score

Get the complete analysis for MEX:RXRX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN62.20
Price
MXN73.63
GF Value